NuPathe's transdermal migraine patch shows promise
This article was originally published in Scrip
Executive Summary
Further results from NuPathe's pivotal Phase III trial of its lead product, Zelrix, an iontophoretic transdermal sumatriptan patch, in migraine patients, show that it has met its primary and secondary efficacy endpoints, the company reports. The product could become the first and only transdermal patch approved for the treatment of acute migraine.